1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma. - Ludwig, J.A.; Federman, N.; Anderson, P.; Macy, M.E.; Davis, L.E.; Riedel, R.F.; Muscal, J.A.; Daw, N.C.; Ratan, R.; Toretsky, J.; Ianopulos, X.; Hsu, F.J.; et al. (Annals of Oncology, 2020)